On Monday, Array Biopharma (ARRY) shares gained 80% after the company announced positive results in its phase 3 clinical trial treating patients with metastatic melanoma. More specifically the clinical trial met on the primary endpoint of the phase 3 study. Metastatic melanoma is skin cancer that has advanced to a later stage, and it typically far more difficult to treat. 

One thing to note is that the patients with metastatic melanoma had the type with the BRAF mutation. The trial combined two experimental drugs from Array known as encorafenib, and binimetinib. Both of these drugs were being tested against the placebo in the study, Zelboraf, which comes from Roche (RHHBY). 

The conclusion of the analysis was that the combination drug achieved a progression-free survival rate of 14.9 months compared to Zelboraf only improving progression-free survival by 7.9 months. Array Biopharma shares should continue to run as people realize the value of the combination therapy. There is no doubt that these tremendous results will bring a lot of new investors into the fold, and the stock should head higher in the weeks to come.